| Web: | mayocliniclabs.com |
|---|---|
| Email: | mcl@mayo.edu |
| Telephone: | 800-533-1710 |
| International: | +1 855-379-3115 |
| Values are valid only on day of printing | |
| Web: | mayocliniclabs.com |
|---|---|
| Email: | mcl@mayo.edu |
| Telephone: | 800-533-1710 |
| International: | +1 855-379-3115 |
| Values are valid only on day of printing | |
For patients affected by systemic lupus erythematosus (SLE), managing disease activity is integral to preventing organ damage and other adverse outcomes.
Mayo Clinic Laboratories’ portfolio of novel lupus testing, offered in collaboration with Progentec Diagnostics, objectively assesses multiple pro-inflammatory soluble immune mediators in the blood to characterize and screen for possible increased clinical disease activity and ascertain the future risk of a clinical disease flare. Arming clinicians with this information has the potential to enhance disease management, prevent organ damage, and improve patient outcomes.
10x
10x higher healthcare costs to treat severe flares compared to mild flares1
65–70%
65–70% of patients with SLE experience at least one clinical disease flare annually1
40–66%
40–66% of patients with SLE may experience clinical disease flare even after achieving 5–10 years of remission2
33%
33% of patients with SLE who achieved remission may experience a clinical disease flare after withdrawing immunosuppressant medication3
LUPUS Test menu
More information
New research guides testing approach
Attaining an accurate measurement of a patient’s immune activity level, which corresponds to current disease severity and future flare potential, can allow for proactive SLE disease management rather than a reactive approach necessitated by the use of validated yet time-consuming clinical disease activity measures.
New research suggests that underlying immune pathway dysregulation, measured in plasma cytokines and chemokines, is the most accurate indicator of SLE disease activity and risk of flare. Measuring these protein biomarkers through laboratory testing can reveal disease characteristics resulting from immune dysregulation that can inform and guide clinical disease management.
Use of objective and sensitive biomarker measurements to gauge clinical disease activity and risk of flare has the potential to prevent organ damage and improve patient outcomes through proactive clinical disease management and pre-emptive treatment.
The Progentec aiSLE® DX Lupus Disease Activity Index assay characterizes patients with active clinical and/or serologic disease versus patients with low or quiescent disease. The well-defined set of 10 biomarkers measured in this assay encompasses the breadth of immune dysregulation associated with SLE and reflects the immune status of individual patients. Results from this test can be used to help determine the necessary frequency of clinical assessments, guide clinical disease management, and evaluate early response to treatment.
Key testing
Advantages
Highlights
As a successful outcome of the collaboration announced in 2023, Progentec’s proprietary biomarker blood tests for the proactive management of systemic lupus erythematosus are now available through Mayo Clinic Laboratories.
Mayo Clinic Laboratories, a leading global reference laboratory, and Progentec Diagnostics, a digital health and biomarker technology-based company focused on autoimmune conditions, today announced a strategic collaboration to bring Progentec’s suite of proprietary biomarker blood tests for the proactive management of autoimmune diseases to market. The collaboration aims to increase accessibility for providers and patients across the U.S. and select global markets.
The Progentec aiSLE® DX Lupus Flare Risk Index quantifies pro-inflammatory and regulatory immune soluble mediators to calculate a flare risk index, which assigns an individuals score associated with a patient's risk of a forthcoming flare. The index score reported for the test predicts the risk of clinical disease flare over the next 12 weeks.
Key testing
Advantages
Highlights
As a successful outcome of the collaboration announced in 2023, Progentec’s proprietary biomarker blood tests for the proactive management of systemic lupus erythematosus are now available through Mayo Clinic Laboratories.
Mayo Clinic Laboratories, a leading global reference laboratory, and Progentec Diagnostics, a digital health and biomarker technology-based company focused on autoimmune conditions, today announced a strategic collaboration to bring Progentec’s suite of proprietary biomarker blood tests for the proactive management of autoimmune diseases to market. The collaboration aims to increase accessibility for providers and patients across the U.S. and select global markets.